(19) 대한민국특허청(KR) (12) 공개특허공보(A) - Questel

[0688]
prostate cancer xenografts in nude mice, Prostate, 2001 Jun 15;48(1):47-53; Smith PC, et al,
Interleukin-6 and prostate cancer progression, Cytokine Growth Factor Rev., 2001 Mar;12(1):33-40;
Chung TD, et al, Characterization of the role of IL-6 in the progression of prostate cancer, Prostate,
1999 Feb 15;38(3):199-207; Okamoto M, et al, Interleukin-6 as a paracrine and autocrine growth factor
in human prostatic carcinoma cells in vitro, Cancer Res., 1997 Jan 1;57(1):141-6; Reittie JE, et al,
Interleukin-6 inhibits apoptosis and tumor necrosis factor induced proliferation of B-chronic
lymphocytic leukemia, Leuk Lymphoma, 1996 Jun;22(1-2):83-90, follow 186, color plate VI; Sugiyama H,
et al, The expression of IL-6 and its related genes in acute leukemia, Leuk Lymphoma, 1996 Mar;21(1-
2):49-52; Bataille R, et al, Effects of an anti-interleukin-6 (IL-6) murine monoclonal antibody in a
patient with acute monoblastic leukemia, Med Oncol Tumor Pharmacother., 1993;10(4):185-8; Kedar I, et
al, Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a
fraction of metastatic renal cell cancer patients who failed IL-2-based therapy, Int J Cancer, 2004
Jun 10;110(2):260-5; Angelo LS, Talpaz M, Kurzrock R, Autocrine interleukin-6 production in renal cell
carcinoma: evidence for the involvement of p53, Cancer Res., 2002 Feb 1;62(3):932-40; Nishimoto N,
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease, Blood,
2005 Oct 15;106(8):2627-32, Epub 2005 Jul 5; Katsume A, et al, Anti-interleukin 6 (IL-6) receptor
antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice, Cytokine, 2002
Dec 21;20(6):304-11; Nishimoto N, et al, Improvement in Castleman's disease by humanized anti-
interleukin-6 receptor antibody therapy, Blood, 2000 Jan 1;95(1):56-61; Screpanti I, Inactivation of
the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP betamice, J Exp Med.,
1996 Oct 1;184(4):1561-6; Hsu SM, et al, Expression of interleukin-6 in Castleman's disease, Hum
Pathol., 1993 Aug;24(8):833-9; Yoshizaki K, et al, Pathogenic significance of interleukin-6 (IL 6/BSF-
2) in Castleman's disease, Blood, 1989 Sep;74(4):1360-7; Nilsson MB, et al, Interleukin-6, secreted by
human ovarian carcinoma cells, is a potent proangiogenic cytokine, Cancer Res., 2005 Dec
1;65(23):10794-800; Toutirais O, et al, Constitutive expression of TGF-betal, interleukin-6 and
interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma, Eur
Cytokine Netw., 2003 Oct-Dec;14(4):246-55; Obata NH, et al, Effects of interleukin 6 on in vitro cell
attachment, migration and invasion of human ovarian carcinoma, Anticancer Res., 1997 Jan-Feb;17
(lA):337-42; Dedoussis GV, et al, Endogenous interleukin 6 conveys resistance to cis-
diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line, Exp Cell Res., 1999
Jun 15;249(2):269-78; Borsellino N, et al, Blocking signaling through the Gp130 receptor chain by
interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide
and cisplatin-mediated cytotoxicity, Cancer, 1999 Jan 1;85(1):134-44; Borsellino N, et al, Endogenous
interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated
cytotoxicity of human prostate carcinoma cell lines, Cancer Res., 1995 Oct 15;55(20):4633-9; Mizutani
Y, et al, Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by
anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody; Cancer
Res., 1995 Feb 1;55(3):590-6; Yusuf RZ, et al, Paclitaxel resistance: molecular mechanisms and
pharmacologic manipulation, Curr Cancer Drug Targets, 2003 Feb;3(1):1-19; Duan Z, et al,
Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-20S human osteosarcoma cells,
Cytokine, 2002 Mar 7;17(5):234-42; Conze D, et al, Autocrine production of interleukin 6 causes
multidrug resistance in breast cancer cells, Cancer Res., 2001 Dec 15;61(24):8851-8; Rossi JF, et al,
Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of
melphalan in multiple myeloma: results of a pilot study including biological aspects, Bone Marrow
Transplant, 2005 Nov;36(9):771-9; 그리고 Tonini G, et al, Oxaliplatin may induce cytokine-release
syndrome in colorectal cancer patients, J BiolRegul Homeost Agents, 2002 Apr-Jun;16 (2):105-9; 이들 각
각의 내용은 본 발명에 그 전체가 참조로서 편입된다).
공개특허 10-2011-0112308
본 발명의 또 다른 구체예에서, 본 명세서에서 기술된 항-IL-6 항체, 또는 이들의 단편 또는 변이체는 허혈성
심장 질환, 동맥경화증, 비만, 당뇨병, 천식, 다발성 경화증, 알츠하이머병, 뇌혈관 질환, 발열, 급성기 반응,
알레르기, 빈혈, 염증의 빈혈(만성 질환의 빈혈), 고혈압, 우울증, 만성 질환과 연관된 우울증, 혈전증, 혈소판
- 105 -